Background-Individuals with diabetes mellitus and pre-diabetes mellitus are at particularly high risk of incident heart failure or death, even after accounting for known confounders. Nevertheless, the extent of impairments in cardiac structure and function in elderly individuals with diabetes mellitus and pre-diabetes mellitus is not well known. We aimed to assess the relationship between echocardiographic measures of cardiac structure and function and dysglycemia. Methods and Results-We assessed measures of cardiac structure and function in 4419 participants without prevalent coronary heart disease or heart failure who attended the Atherosclerosis Risk In the Community (ARIC) visit 5 examination (2011-2013) and underwent transthoracic echocardiography (age, 75±6 years; 61% women, 23% black). Subjects were grouped across the dysglycemia spectrum as normal (39%), pre-diabetes mellitus (31%), or diabetes mellitus (30%) based on medical history, antidiabetic medication use, and glycated hemoglobin levels. Glycemic status was related to measures of cardiac structure and function. Worsening dysglycemia was associated with increased left ventricular mass, worse diastolic function, and subtle reduction in left ventricular systolic function (P≤0.01 for all). For every 1% higher glycated hemoglobin, left ventricular mass was higher by 3.0 g (95% confidence interval, 1.5-4.6 g), E/E′ by 0.5 (95% confidence interval, 0.4-0.7), and global longitudinal strain by 0.3% (95% confidence interval, 0.2-0.4) in multivariable analyses. Conclusions-In a large contemporary biracial cohort of elderly subjects without prevalent cardiovascular disease or heart failure, dysglycemia was associated with subtle and subclinical alterations of cardiac structure, and left ventricular systolic and diastolic function. It remains unclear whether these are sufficient to explain the heightened risk of heart failure in individuals with diabetes mellitus. (Circ Heart Fail. 2015;8:448-454.
I ndividuals with diabetes mellitus are at particularly high risk of cardiovascular disease, incident heart failure (HF) and death, even after accounting for known confounders. [1] [2] [3] [4] [5] [6] Although a specific cardiomyopathy characterized by diffuse myocardial fibrosis has been identified in some individuals with diabetes mellitus, 7-9 the extent of impairments in cardiac structure and function in elderly individuals with diabetes mellitus and pre-diabetes mellitus is not well known. Previous studies have shown that individuals with diabetes mellitus have increased left ventricular (LV) wall thickness and mass, and impaired diastolic function 10, 11 in the absence of overt LV systolic dysfunction 12 ; the alterations in cardiac structure and function in less impaired glycemic states or among elderly individuals without prevalent cardiovascular disease are less well described.
Clinical Perspective on p 454
To understand the relationship between dysglycemia and cardiac structure and function, we analyzed echocardiographic data from of the Atherosclerosis Risk in Communities (ARIC) study who attended the fifth visit in 2011 to 2013 and were free of prevalent coronary heart disease (CHD) or HF. We hypothesized that worse dysglycemia, characterized as pre-diabetes mellitus and diabetes mellitus, would be associated with greater abnormalities of cardiac structure and diastolic and systolic function before the development of overt cardiac disease.
Methods

Study Population
ARIC is an ongoing, prospective observational study of the natural history of atherosclerotic diseases and cardiovascular risk factors. The design and sampling of the ARIC study has been described previously. 13 Briefly, individuals were recruited from 4 communities (Forsyth County, NC; Jackson, MS; Minneapolis, MN; and Washington County, MD) to participate in a prospective study of cardiovascular disease between 1987 and 1989. Of all 15 792 participants who were enrolled in ARIC at the first examination, a total of 6533 participants attended the fifth visit between 2011 and 2013 for a standardized physical examination, interviewer-administered questionnaires, and a comprehensive echocardiographic examination. 14 For the present analysis, we excluded subjects of nonwhite or nonblack race (n=18), without echocardiographic examination (n=418), with prevalent heart disease (HF, CHD, previous myocardial infarction, cardiac pacemaker or defibrillator in place; n=1518), or valvular disease (moderate or severe, previous valve repair or replacement; n=138).
Institutional review boards approved the study protocol at each field center. All participants provided written informed consent, and study procedures were conducted in accordance with institutional guidelines about the protection of human subjects.
Dysglycemia Classification
On the basis of annual telephone interviews, comprehensive questionnaires, medication lists, and results of visit 5 laboratory tests for glycated hemoglobin (HbA1c) levels, we classified participants into 1 of 3 groups 15,16 : (1) diabetes mellitus: known diabetes mellitus or on anti-diabetes mellitus medications, visit 5-HbA1c ≥ 6.5%; (2) pre-diabetes mellitus: no known diabetes mellitus, but visit 5-HbA1c between 5.7% and 6.4%; and (3) normal: no known diabetes mellitus at visits 1 to 5 and annual follow-up data, and visit 5-HbA1c < 5.7%. We identified a group of subjects with undiagnosed diabetes mellitus defined as unknown diabetes mellitus and not on anti-diabetes mellitus medications but with elevated HbA1c. Given the small size of this group, we combined it with the diabetes mellitus group. In addition, we also categorized this cohort into 3 groups based on fasting glucose values at visit 5: (1) diabetes mellitus: known diabetes mellitus or on anti-diabetes mellitus medications, visit 5-fasting glucose ≥126 mg/ dL or nonfasting glucose>200 mg/dL; (2) pre-diabetes mellitus: no known diabetes mellitus, but visit 5-fasting glucose 100 to 126 mg/ dL; and (3) normal: no known diabetes mellitus at visits 1 to 5 and annual follow-up data, and visit 5-fasting glucose level <100 mg/mL.
Echocardiographic Analysis
Details about the design and protocol of the ARIC visit 5 echocardiographic study, and reproducibility data, were previously published. 14 Briefly, all studies were prospectively acquired on Philips IE33 machines by trained sonographers according to a study-specific comprehensive echocardiographic protocol. Analyses of 2-dimensional, Doppler, and tissue Doppler echocardiography were performed by expert sonographers and over-read by echocardiographers in a central echo core laboratory. The current analysis focused on markers of LV structure: mean LV wall thickness, LV mass, LV end-diastolic diameter, relative wall thickness (RWT), LV end-diastolic volume; LV diastolic function: left atrial volume and height-indexed LA volume, early mitral inflow peak velocity (E wave), early mitral annulus tissue Doppler velocity (e′) and E/e′; systolic function: LV ejection fraction, global longitudinal strain (GLS) derived from speckle-tracking echocardiography and right ventricular (RV) fractional area change.
Statistical Analysis
Baseline characteristics were compared across categories using nonparametric trend test for continuous variables 17 and χ 2 test for trend for binary variables. Echocardiographic data are presented as unadjusted and multivariable-adjusted means with P values estimated from linear regression for trend across dysglycemia categories. Adjusted models included age, sex, race, field center, body mass index, body surface area, systolic blood pressure, heart rate, history of hypertension, current smoking status, and chronic kidney disease status. If a significant trend across categories was detected, then pairwise comparisons of dysglycemia categories were made. We assessed sex-based interactions between echocardiographic measures and dysglycemia categories. If the P for sex interaction was <0.05, then sex-specific trend tests were additionally conducted. To flexibly assess the continuous relationship between echocardiographic measures and HbA1c level among all patients (regardless of known diabetes mellitus status), restricted cubic spline regression models were used with 3 knots at the recommended 10th, 50th, and 90th percentiles. 18 P values <0.05 were considered significant. All analyses were conducted using STATA (version 12).
Results
Overall, 4419 ARIC visit 5 participants who were free of prevalent heart disease (no evidence of prevalent HF, previous myocardial infarction, or CHD) were included in this analysis. Diabetes mellitus was prevalent in 1256 (29.0%) of those with both glucose and HbA1c measurements available (n=4334). Using clinical categories of HbA1c, undiagnosed diabetes mellitus was found in 64 subjects (1.5%), and pre-diabetes mellitus in 1324 (30.6%) subjects. When classified by clinical categories of glucose levels, the prevalence of undiagnosed diabetes mellitus and pre-diabetes mellitus was 4.2% (n=183) and 38.5% (n=1667), respectively. Overall, there was agreement between the glucose-based and the HbA1c-based diagnoses in 67% of the patients ( Table I in the Data Supplement) . Table 1 shows participants' characteristics according to dysglycemia status defined by clinical categories of HbA1c with undiagnosed and known diabetes mellitus combined in 1 category. Subjects with diabetes mellitus were more likely to be black, have a history of hypertension, and evidence of chronic kidney disease by an estimated glomerular filtration rate <60 mL/min per 1.73 m. 2 Compared with subjects with diabetes mellitus or pre-diabetes mellitus, those in the normal glycemia category had lower body mass index, heart rate and high sensitivity-C-reactive protein, and higher low-density lipoprotein and high-density lipoprotein levels (Table 1) .
LV wall thickness, mass, and RWT were significantly higher in subjects with diabetes mellitus than in those without diabetes mellitus, or pre-diabetes mellitus even after adjustment for age, sex, race, center, body mass index, body surface area, systolic blood pressure, heart rate, hypertension, smoking, and chronic kidney disease ( Table 2 ). The mean multivariableadjusted LV mass of subjects with diabetes mellitus (146 g) was higher than that of subjects with pre-diabetes mellitus (142 g) or no diabetes mellitus (143 g; P for trend=0.03). In multivariable models, participants with pre-diabetes mellitus had higher interventricular septal wall thickness and RWT compared with normal subjects. LV end-diastolic and end-systolic volumes were smaller in subjects with diabetes mellitus and pre-diabetes mellitus than in those in the normal category likely a consequence of wall thickness being greater ( Table 2) .
All measures of LV diastolic function, including early to late mitral inflow velocities (E:A ratio), lateral and septal mitral annulus relaxation velocities, and mitral inflow to mitral relaxation velocity ratio (E over E′), were worse in subjects with diabetes mellitus in multivariable analyses ( Table 2) . Subjects with pre-diabetes mellitus also demonstrated worse measures of diastolic function than normal subjects, specifically, tissue Doppler derived measures. The early mitral inflow velocity:annular velocity ratio was below the accepted upper limit of normal (15 for septal and 12 for lateral), suggesting on average normal filling pressures. However, E/E′ was higher in both subjects with pre-diabetes mellitus and diabetes mellitus compared with subjects in the normal group.
LV ejection fraction was within the normal range in the majority of participants and similar across dysglycemia categories (66±6%; P=0.5). GLS, while also in the normal range, was worse in subjects with pre-diabetes mellitus (−18.1±2.5%) or diabetes mellitus (−17.8±2.4%) compared with subjects with no dysglycemia (−18.5±2.3%; P for trend <0.001; Table 2 ). Right ventricular systolic function was significantly associated with dysglycemia status in univariable analyses (P for trend=0.02), but not in multivariable analyses (P for trend=0.33).
Using HbA1c as continuous marker of dysglycemia in multivariable regression analyses, higher HbA1c levels were significantly associated with worse LV mass, worse markers of LV diastolic and systolic function, but not RV systolic function (Figure) . For every 1% higher HbA1c, LV mass was higher by 3.0 g (95% confidence interval [CI], 1.5-4.6 g), E over E′ by 0.5 (95% CI, 0.4-0.7), and GLS by 0.3% (95% CI, 0.2-0.4).
Race and Gender Interactions
We found an interaction between dysglycemia status and sex, suggesting that women with diabetes mellitus had thicker interventricular septal wall than normoglycemic women, whereas men had similar LV septal wall thickness (multivariable-adjusted P for interaction=0.03; Table II in the Data Supplement). This interaction was not, however, observed with other measures of LV structure, such as mean wall thickness or RWT. There was no interaction between sex and dysglycemia categories with regards to LV ejection fraction or measures of diastolic function. An interaction (P for interac-tion=0.02) for sex was observed for the relationship between HbA1c and GLS, where women demonstrated a stronger statistical relationship (linear β coefficient, 0.3; 95% CI, 0.2-0.5; P<0.001) than men (linear β coefficient, 0.2; 95% CI, 0.04-0.4; P=0.02).
We did not observe any statistical interaction by race for the relationship between dysglycemia categories or HbA1c levels and echo measures of cardiac structure and function (data not shown; P value for interactions >0.05).
Discussion
In this large biracial cohort of elderly subjects without prevalent CHD or HF, we demonstrate that both diabetes mellitus and pre-diabetes mellitus are associated with increased LV mass, worse diastolic function, and subtle reduction in LV systolic function. These findings suggest that hyperglycemic states may contribute to subtle subclinical impairments in cardiac structure and function and propose a potential mechanism by which diabetes mellitus may lead to an increased risk of HF independently of prevalent coronary disease.
Increased LV mass and wall thickness are established risk factors for mortality and HF. [19] [20] [21] In our analyses, nearly all measures of LV wall thickness and mass and prevalence of LV hypertrophy were increased in subjects with diabetes mellitus compared with those in the normal glycemia category. Subjects with pre-diabetes mellitus showed a thicker interventricular septum and higher RWT in multivariable-adjusted analyses and similar trends in other measures that were not statistically significant. Whether the magnitude of the differences observed is sufficient to be related to worse outcomes in our cohort remains to be assessed.
The Framingham Heart Study showed that worsening glucose tolerance and insulin resistance were associated with increased LV mass and wall thickness, a finding that was more striking in women than in men. 11, 22 In our analyses, although we found that diabetes mellitus was associated with increased LV mass and wall thickness overall, this was more apparent in women only for interventricular septal wall thickness, and height-indexed LV mass. The association between HbA1c and LV mass was not modified by sex (P for interaction=0.4). The sex interaction with measures of wall thickness and LV mass was not seen in other studies, such as the Strong Heart Study 10 or the Cardiovascular Health Study. 12 More importantly, it seems that the magnitude of the association between LV mass and HbA1c although statistically significant may not be clinically important. In our analyses, the change in LV associated with a 1% increase in HbA1c was rather small (3.0 g; 95% CI, 1.5-4.6 g), and the average difference between subjects with diabetes mellitus and without was ≈11 g, similar in magnitude to findings from other studies, 10, 22 including an MRI-based study. 23 Whether these small differences in LV mass can be related to future outcomes remains to be seen. For comparison, for each increment of 50 g (per m) in LV mass, the risk of death was increased by 1.5 in men and 2.0 in women in the Framingham Heart Study. 19 Alterations in diastolic function have been observed in diabetic cardiomyopathy and have been ascribed to several potential mechanisms, including abnormalities of free fatty acid metabolism, impaired calcium homeostasis, or increased myocytes apoptosis [24] [25] [26] among others. The prevalence of diastolic dysfunction among subjects with diabetes mellitus has varied across studies owing to differing populations and methods of assessing diastology. [27] [28] [29] [30] [31] We show a lower early to late mitral inflow velocities ratio (E-A ratio) in subjects with diabetes mellitus compared with those with pre-diabetes mellitus or in the normal group, suggesting worse diastolic function. However, mitral inflow-based measures of diastolic function are not generally considered reliable because they are extremely load dependent and can vary unpredictably as diastolic function worsens. 32 More reliable measures of early diastolic annular relaxation velocities 32 were lower with worsening dysglycemia without evidence that either sex or race modified these relationships. LV filling pressures, as estimated by E/e′, although mostly in the normal range, were also positively associated with dysglycemia category and HbA1c. Previous studies have shown that diabetic individuals develop HF subsequent to myocardial infarction at twice the rate of those without diabetes mellitus with similar heart sizes and ejection fraction. 33 That diastolic function seems to worsen with dysglycemia suggests a mechanism whereby individuals with diabetes mellitus may be at increased risk of HF.
In this selected study population free of prevalent CHD or HF and a normal LV ejection fraction, we found no association between LV ejection fraction and dysglycemia category or hemoglobin A1c. Indeed, the association between LV systolic function and dysglycemia has been inconsistent across previous studies. The Cardiovascular Health Study showed no association between severity of diabetes mellitus and LV fractional shortening 12 and an early analysis from the Framingham Heart Study showed a slight decrease in fractional shortening only among men. 11 In a cardiac MRI study of 1603 Framingham Study Offspring participants, there was no association between diabetes mellitus and MRI-derived LV ejection fraction. 34 Nevertheless, we found that GLS, a more sensitive measure of systolic function than ejection fraction, 35, 36 was related to worsening dysglycemia and increasing HbA1c for both men and women. The association between HbA1c and GLS seemed to be stronger for women than for men. Other smaller studies [37] [38] [39] [40] have also demonstrated preclinical decreases in LV systolic function in patients with diabetes mellitus, possibly related to duration of diabetes mellitus or severity of nephropathy. It is important to note that our findings were independent of LV hypertrophy or hypertension status as surrogates for end-organ damage from long-standing hypertension.
We also show an association between RV function and diabetes mellitus status in unadjusted analyses, albeit it was not statistically significant in multivariable models. The association between HbA1c and RV function was also not significant in adjusted analyses. Although a handful of small studies have shown RV impairments associated with diabetes mellitus, [41] [42] [43] there is, however, little data about the prognostic value of RV function in a nondisease state and its relationship with HF incidence. Although RV fractional area change is a validated measure of RV systolic function that has been correlated with an MRI-derived ejection fraction 44, 45 and associated with clinical outcomes, 46 it is possible that subclinical impairments in RV function related to dysglycemia cannot be captured by RV fractional area change measurement and may explain the lack of association in our analyses. Several limitations of this analysis should be noted. The cross-sectional nature of this analysis cannot establish longitudinal trends or causes but describes associations. ARIC visit 5 was completed in 2011 to 2013, and thus we cannot assess the relationship between these measures of cardiac structure and function and outcomes at this time. We could only assess cardiac structure and function in ARIC fifth visit participants who were free of prevalent heart disease, and thus these results may not be generalizable to all elderly subjects. Moreover, despite excluding ARIC participants with prevalent CHD or HF, the prevalence of pre-diabetes mellitus or diabetes mellitus (61%) in the ARIC cohort was high compared with national prevalence numbers 47 (48% among subjects >65 years). In an analysis performed in the Framingham Heart Study, where the mean age was <60 years, only 20% of the cohort had pre-diabetes mellitus or diabetes mellitus, 22 whereas in a Strong Heart Study analysis (n=2754; mean age, 60 years), 66% had diabetes mellitus. 10 Our measure of dysglycemia was based on single laboratory values HbA1c levels, in addition to self-reports or history of medication use, and there was no glucose tolerance testing or repeated measurements performed. Although self-reported diabetes mellitus is known to be reliable and highly specific, 15 laboratory measures need to be replicated in the clinical setting to confirm a diagnosis. Finally, as with all observational analyses, we cannot rule out the possibility of residual confounding, especially given that hypertension was highly prevalent in our cohort (80%), and adjusting for this risk factor may not have been sufficient.
We show in a large cohort of elderly men and women free of heart disease that although most echocardiographic measures of cardiac structure and function are in the range of normal values, dysglycemia is associated with higher LV mass, worse diastolic function, and worse LV systolic function. These associations seem to be independent of race and sex and remain statistically significant after multivariable adjustments but with admittedly an unknown clinical significance. Further analyses investigating whether these relationships are predictive of worse prognosis need to be performed to test whether these findings represent a potential mechanism that underlies the exceedingly high risk of HF and death among subjects with dysglycemia.
